CN111973480A - Oral care composition and application thereof - Google Patents
Oral care composition and application thereof Download PDFInfo
- Publication number
- CN111973480A CN111973480A CN201911401585.7A CN201911401585A CN111973480A CN 111973480 A CN111973480 A CN 111973480A CN 201911401585 A CN201911401585 A CN 201911401585A CN 111973480 A CN111973480 A CN 111973480A
- Authority
- CN
- China
- Prior art keywords
- oral care
- toothpaste
- sodium
- oral
- cannabidiol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims abstract description 49
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims abstract description 49
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims abstract description 49
- 229950011318 cannabidiol Drugs 0.000 claims abstract description 49
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims abstract description 49
- 239000000606 toothpaste Substances 0.000 claims abstract description 49
- GEYJUFBPCGDENK-UHFFFAOYSA-M sodium;3,8-dimethyl-5-propan-2-ylazulene-1-sulfonate Chemical compound [Na+].CC(C)C1=CC=C(C)C2=C(S([O-])(=O)=O)C=C(C)C2=C1 GEYJUFBPCGDENK-UHFFFAOYSA-M 0.000 claims abstract description 47
- 229940034610 toothpaste Drugs 0.000 claims abstract description 47
- 229940046011 buccal tablet Drugs 0.000 claims abstract description 4
- 239000006189 buccal tablet Substances 0.000 claims abstract description 4
- 229940112822 chewing gum Drugs 0.000 claims abstract description 4
- 235000015218 chewing gum Nutrition 0.000 claims abstract description 4
- 239000000551 dentifrice Substances 0.000 claims abstract description 4
- 239000002324 mouth wash Substances 0.000 claims abstract description 4
- 229940051866 mouthwash Drugs 0.000 claims abstract description 4
- 239000003906 humectant Substances 0.000 claims description 15
- 239000003755 preservative agent Substances 0.000 claims description 13
- 230000002335 preservative effect Effects 0.000 claims description 13
- 239000004094 surface-active agent Substances 0.000 claims description 12
- 239000000853 adhesive Substances 0.000 claims description 10
- 230000001070 adhesive effect Effects 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 235000003599 food sweetener Nutrition 0.000 claims description 9
- 239000003765 sweetening agent Substances 0.000 claims description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 159000000000 sodium salts Chemical class 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000000230 xanthan gum Substances 0.000 claims description 6
- 229920001285 xanthan gum Polymers 0.000 claims description 6
- 235000010493 xanthan gum Nutrition 0.000 claims description 6
- 229940082509 xanthan gum Drugs 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 108700004121 sarkosyl Proteins 0.000 claims description 5
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 5
- 235000010234 sodium benzoate Nutrition 0.000 claims description 5
- 239000004299 sodium benzoate Substances 0.000 claims description 5
- 229940065859 sodium cocoyl glycinate Drugs 0.000 claims description 5
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 claims description 5
- 229940045885 sodium lauroyl sarcosinate Drugs 0.000 claims description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 5
- IKGKWKGYFJBGQJ-UHFFFAOYSA-M sodium;2-(dodecanoylamino)acetate Chemical compound [Na+].CCCCCCCCCCCC(=O)NCC([O-])=O IKGKWKGYFJBGQJ-UHFFFAOYSA-M 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 239000004376 Sucralose Substances 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 claims description 4
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims description 4
- 229940043256 calcium pyrophosphate Drugs 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000007872 degassing Methods 0.000 claims description 4
- 235000019821 dicalcium diphosphate Nutrition 0.000 claims description 4
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 4
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229920001206 natural gum Polymers 0.000 claims description 4
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 235000019408 sucralose Nutrition 0.000 claims description 4
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229960003415 propylparaben Drugs 0.000 claims description 3
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- 206010061218 Inflammation Diseases 0.000 abstract description 13
- 230000004054 inflammatory process Effects 0.000 abstract description 12
- 239000000047 product Substances 0.000 abstract description 11
- 208000002193 Pain Diseases 0.000 abstract description 10
- 210000002200 mouth mucosa Anatomy 0.000 abstract description 10
- 230000036407 pain Effects 0.000 abstract description 10
- 208000007565 gingivitis Diseases 0.000 abstract description 7
- 208000007117 Oral Ulcer Diseases 0.000 abstract description 6
- 208000002399 aphthous stomatitis Diseases 0.000 abstract description 6
- 201000001245 periodontitis Diseases 0.000 abstract description 6
- 231100000344 non-irritating Toxicity 0.000 abstract description 3
- 229940023486 oral product Drugs 0.000 abstract description 3
- 239000013588 oral product Substances 0.000 abstract description 3
- 239000000668 oral spray Substances 0.000 abstract description 3
- 229940041678 oral spray Drugs 0.000 abstract description 3
- 230000009044 synergistic interaction Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 238000009472 formulation Methods 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 6
- 240000008154 Piper betle Species 0.000 description 5
- 235000008180 Piper betle Nutrition 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 4
- 229960004242 dronabinol Drugs 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 206010018276 Gingival bleeding Diseases 0.000 description 3
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 3
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 3
- 229940120668 salicin Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical class C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- KKMPSGJPCCJYRV-UHFFFAOYSA-N Nitidine Chemical compound C1=C2C3=[N+](C)C=C4C=C(OC)C(OC)=CC4=C3C=CC2=CC2=C1OCO2 KKMPSGJPCCJYRV-UHFFFAOYSA-N 0.000 description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 2
- 241000180649 Panax notoginseng Species 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000003265 stomatitis Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010018286 Gingival pain Diseases 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- -1 anti-inflammatory Substances 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000004513 dentition Anatomy 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 208000011759 gum bleeding Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- VIZXMHCBZLGUET-UHFFFAOYSA-N sodium gualenate Chemical compound CC(C)C1=CC=C(C)C2=C(S(O)(=O)=O)C=C(C)C2=C1 VIZXMHCBZLGUET-UHFFFAOYSA-N 0.000 description 1
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000036346 tooth eruption Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to an oral care composition and application thereof, wherein the oral care composition comprises cannabidiol and sodium azulene sulfonate. The invention creatively discovers that the cannabidiol and the sodium azulene sulfonate have a synergistic interaction effect in oral care, compared with the single cannabidiol or the sodium azulene sulfonate, the composition consisting of the cannabidiol and the sodium azulene sulfonate has better effects of resisting inflammation, repairing oral mucosa and easing pain, has obvious curative effects on oral problems such as periodontitis, gingivitis, oral ulcer and the like, and is soft in taste, non-irritating and good in experience degree after being prepared into an oral product. The composition can be used in oral care products such as toothpaste, dentifrice, mouthwash, oral spray, oral patch, chewing gum or buccal tablet.
Description
Technical Field
The invention belongs to the technical field of oral care products, and particularly relates to an oral care composition and application thereof, in particular to an oral care composition, an oral care toothpaste and a preparation method thereof.
Background
Periodontitis, gingivitis, oral ulcer and the like are increasingly developed due to accelerated life rhythm, increased working pressure, poor living habits and the like, particularly for urban people with fast rhythm, the incidence rate is higher, and most of adult people suffer from periodontitis in different degrees. Oral diseases are highly developed due to local irritation of periodontal supporting tissues in the oral cavity (e.g., tartar, food impaction, defective restorations, etc.), long-term mechanical irritation, dentition misalignment, excessive load on the dental occlusal force, improper tooth brushing method, chemicals, burns, vitamin C deficiency, bacterial growth in the oral cavity, etc. For people who eat betel nuts for a long time, the betel nuts are often chewed unconsciously, and the friction between the crude fibers of the betel nuts and the oral mucosa can cause local trauma, mucosal injury, gingival degeneration and submucosal fibrosis, thereby causing the possibility of canceration of the oral cavity.
CN101023914 discloses a toothpaste containing notoginseng extract and its preparation method, comprising 0.07-1.2% of total weight percent of notoginseng fluid extract equivalent to 0.8-2g of original medicine per 1 ml; the other components comprise 30 to 55 percent of abrasive, 15 to 30 percent of wetting agent, 0.6 to 1.5 percent of adhesive, 2 to 2.7 percent of foaming agent, the balance of deionized water, a small amount of essence and the like. Besides cleaning teeth, the invention has the efficacy of preventing and treating periodontitis, gingivitis, gingival bleeding, oral ulcer and the like, and has low cost and obvious public health value.
CN104644845A discloses a compound traditional Chinese medicine toothpaste, the total composition of a toothpaste body of the toothpaste body comprises 0.33-1.10% of compound traditional Chinese medicine functional components by weight, the compound traditional Chinese medicine functional components comprise salicin and radix zanthoxyli extracts, the ratio of the salicin and the radix zanthoxyli extracts is 1:10, in the total composition of the toothpaste body, the weight percentage of the salicin in the total composition of the toothpaste body is more than or equal to 0.03%, and the weight percentage of the new rodlike Zanthoxylamide of the radix zanthoxyli and the nitidine in the total composition of the toothpaste body is more than or equal to 0.003%. Compared with the prior art, the compound traditional Chinese medicine toothpaste has the effects of easing pain, resisting inflammation and reducing internal heat, can effectively relieve the discomfort conditions of toothache, gum redness and swelling, gum bleeding and the like, and can meet the requirement of preventing oral problems of consumers.
Most of the existing toothpaste in the market aims at the problem of stomatitis, Chinese herbal medicine components for clearing heat and reducing internal heat are added to relieve symptoms, a certain prevention effect can be achieved for gingival bleeding and periodontal diseases, but the effect on the formed stomatitis is not obvious, and especially for people eating betel nuts for a long time; meanwhile, the toothpaste is not suitable for some blood patients, because the blood of the patients is often high in viscosity and easy to be subjected to vascular embolism, and the tendency is aggravated if some toothpaste containing a hemostatic component is used. There is a need for a more effective oral care product that provides pain relief and reduces oral inflammation.
The cannabinol compounds are active substances contained in cannabis plants, and mainly comprise Tetrahydrocannabinol (THC), Tetrahydrocannabinoid (THCV), Cannabidiol (CBD), Cannabigerol (CBG), and Cannabidivarin (CBDV), and the five of the above substances account for more than 90% of cannabinol compounds. Cannabidiol (CBD), one of the most important non-addictive components in plants, has a variety of pharmacological activities such as anti-spasmodic, anti-inflammatory, anxiolytic, antioxidant, and photodamage repair, and can hinder the adverse effects of Tetrahydrocannabinol (THC) on the human nervous system, and has become a hot spot in drug development. Sodium azulene sulfonate is short for guaiazulene sulfonate, and the ingredient is the effective ingredient of natural plant chamomile.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide an oral care composition and application thereof, and particularly provides the oral care composition, an oral care toothpaste and a preparation method thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
in one aspect, the present invention provides an oral care composition comprising cannabidiol and sodium azulene sulfonate.
The invention creatively discovers that the cannabidiol and the sodium azulene sulfonate have a synergistic interaction effect in oral care, compared with the single cannabidiol or the sodium azulene sulfonate, the composition consisting of the cannabidiol and the sodium azulene sulfonate has better effects of resisting inflammation, repairing oral mucosa and easing pain, has obvious curative effects on oral problems such as periodontitis, gingivitis, oral ulcer and the like, and is soft in taste, non-irritating and good in experience degree after being prepared into an oral product. The composition can be used in oral care products such as toothpaste, dentifrice, mouthwash, oral spray, oral patch, chewing gum or buccal tablet.
Preferably, the mass ratio of sodium azulene sulfonate to cannabidiol in the oral care composition is from 2:1 to 1:100, e.g. 2:1, 1:2, 1:5, 1:10, 1:15, 1:20, 1:25, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90 or 1:100 etc.
When the mass ratio of the sodium azulene sulfonate to the cannabidiol is 2:1-1:100, the synergistic effect phenomenon of the sodium azulene sulfonate and the cannabidiol on the aspects of anti-inflammation, oral mucosa repair and analgesia is more remarkable. And 2:1-1:30 is the mass ratio range with better effect.
Preferably, the mass ratio of sodium azulene sulfonate to cannabidiol in the oral care composition is from 2:1 to 1: 30.
In another aspect, the present invention provides an oral care toothpaste comprising an oral care composition as described above and a toothpaste excipient.
Preferably, the toothpaste auxiliary material comprises a humectant, an abrasive, a binding agent, a surfactant and a preservative.
Preferably, the toothpaste auxiliary material also comprises a sweetening agent.
Preferably, the humectant comprises any one or a combination of at least two of glycerol, sorbitol, propylene glycol, polyethylene glycol or xylitol; the combination of at least two of the above components, such as the combination of glycerin and sorbitol, the combination of propylene glycol and polyethylene glycol, the combination of polyethylene glycol and xylitol, and the like, can be selected in any combination manner, and are not described in detail herein.
Preferably, the abrasive comprises any one or a combination of at least two of calcium carbonate, silica, aluminum hydroxide, calcium hydrogen phosphate dihydrate or calcium pyrophosphate; the combination of at least two of the above-mentioned materials, for example, the combination of calcium carbonate and silica, the combination of silica and aluminum hydroxide, the combination of calcium hydrogen phosphate dihydrate and calcium pyrophosphate, etc., may be selected in any combination manner, and are not described in detail herein.
Preferably, the glue comprises any one or a combination of at least two of cellulose gum, xanthan gum or natural gum; the combination of at least two of the above-mentioned materials, such as the combination of cellulose gum and xanthan gum, the combination of xanthan gum and natural gum, the combination of cellulose gum and natural gum, etc., can be selected in any other combination manner, and is not described in detail herein.
Preferably, the surfactant comprises any one of sodium lauryl sulfate, sodium lauroyl sarcosinate or sodium cocoyl glycinate or a combination of at least two of the above; the combination of at least two of the above compounds, for example, the combination of sodium lauryl sulfate and sodium lauroyl sarcosinate, the combination of sodium lauroyl sarcosinate and sodium cocoyl glycinate, the combination of sodium lauryl sulfate and sodium cocoyl glycinate, and the like, may be selected in any combination manner, and are not described in detail herein.
Preferably, the preservative comprises any one or a combination of at least two of methyl hydroxybenzoate and sodium salt thereof, ethyl hydroxybenzoate and sodium salt thereof, propyl hydroxybenzoate and sodium salt thereof, or sodium benzoate; the combination of at least two of them, for example, the combination of methyl hydroxybenzoate and ethyl hydroxybenzoate, the combination of ethyl hydroxybenzoate and propyl hydroxybenzoate, the combination of sodium propyl hydroxybenzoate and sodium benzoate, and the like, any other combination mode can be selected, and details are not repeated herein.
Preferably, the sweetener comprises sodium saccharin and/or sucralose.
Preferably, the oral care toothpaste comprises, by weight: 0.1-2 parts of oral care composition, 20-75 parts of humectant, 10-50 parts of abrasive, 0.2-2 parts of adhesive, 1-2 parts of surfactant and 0.1-0.5 part of preservative.
The oral care composition may be present in an amount of 0.1 parts, 0.2 parts, 0.4 parts, 0.5 parts, 0.8 parts, 1 part, 1.2 parts, 1.4 parts, 1.5 parts, 1.6 parts, 1.8 parts, 2 parts, or the like by weight.
The humectant can be 20 parts, 25 parts, 30 parts, 35 parts, 40 parts, 45 parts, 50 parts, 60 parts, 70 parts or 75 parts by weight and the like.
The weight portion of the friction agent can be 10 parts, 15 parts, 20 parts, 25 parts, 30 parts, 35 parts, 40 parts, 45 parts or 50 parts and the like.
The adhesive can be 0.2 part, 0.4 part, 0.5 part, 0.8 part, 1 part, 1.2 parts, 1.4 parts, 1.5 parts, 1.6 parts, 1.8 parts or 2 parts by weight.
The surfactant may be present in an amount of 1 part, 1.2 parts, 1.4 parts, 1.5 parts, 1.6 parts, 1.8 parts, 2 parts, or the like.
The preservative can be 0.1 part, 0.15 part, 0.2 part, 0.25 part, 0.3 part, 0.35 part, 0.4 part, 0.45 part or 0.5 part by weight and the like.
In a further aspect, the present invention provides a process for preparing an oral care toothpaste as described above, the process comprising: mixing the components of the formula with water, stirring, homogenizing, grinding, degassing, cooling and aging.
Preferably, the method of preparing the oral care toothpaste comprises:
(1) mixing the adhesive, the preservative, the sodium azulene sulfonate and the sweetening agent with water, sequentially adding the humectant, the surfactant and the cannabidiol, and stirring;
(2) vacuumizing, adding a friction agent, stirring and homogenizing;
(3) grinding, degassing, cooling and aging.
The preparation method of the oral care toothpaste related by the invention is simple and easy to operate, and is suitable for industrial production.
Compared with the prior art, the invention has the following beneficial effects:
the invention creatively discovers that the cannabidiol and the sodium azulene sulfonate have a synergistic interaction effect in oral care, compared with the single cannabidiol or the sodium azulene sulfonate, the composition consisting of the cannabidiol and the sodium azulene sulfonate has better effects of resisting inflammation, repairing oral mucosa and easing pain, has obvious curative effects on oral problems such as periodontitis, gingivitis, oral ulcer and the like, and is soft in taste, non-irritating and good in experience degree after being prepared into an oral product. The composition can be used in oral care products such as toothpaste, dentifrice, mouthwash, oral spray, oral patch, chewing gum or buccal tablet. The oral care composition of the present invention does not contain a hemostatic component, and is suitable for patients with hematopathy.
Detailed Description
To further illustrate the technical means and effects of the present invention, the following further describes the technical solution of the present invention with reference to the preferred embodiments of the present invention, but the present invention is not limited to the scope of the embodiments.
Example 1
This example provides an oral care toothpaste (100g) having the following formulation:
cannabidiol 0.5g
Sodium azulene sulfonate 0.05g
Humectant (sorbitol) 50g
Humectant (glycerin) 5g
30g of abrasive (calcium hydrogen phosphate dihydrate)
0.9g of adhesive (cellulose adhesive)
Surfactant (sodium lauryl sulfate) 1g
0.08g of preservative (methylparaben)
0.04g of preservative (propylparaben)
Sweetener (saccharin sodium) 0.4g
The balance being water
The preparation method comprises the following steps:
(1) mixing the adhesive, the preservative, the sodium azulene sulfonate and the sweetening agent with water, sequentially adding the humectant, the surfactant and the cannabidiol, and stirring;
(2) vacuumizing, adding a friction agent, stirring and homogenizing;
(3) grinding, degassing, cooling and aging.
Example 2
This example provides an oral care toothpaste (100g) having the following formulation:
cannabidiol 0.1g
Sodium azulene sulfonate 0.01g
Humectant (polyethylene glycol) 10g
Humectant (xylitol) 10g
Abrasive (calcium carbonate) 10g
0.4g of adhesive (xanthan gum)
Surfactant (sodium lauroyl sarcosinate) 1g
Preservative (sodium benzoate) 0.1g
Sweetener (sucralose) 0.2g
The balance being water
The preparation process is as in example 1.
Example 3
This example provides an oral care toothpaste (100g) having the following formulation:
cannabidiol 1g
Sodium azulene sulfonate 0.1g
Humectant (polyethylene glycol) 50g
Humectant (sorbitol) 25g
Friction agent (calcium pyrophosphate) 50g
2g of adhesive (xanthan gum)
2g of surfactant (sodium cocoyl glycinate)
Preservative (sodium benzoate) 0.1g
Sweetener (sucralose) 0.2g
The balance being water
The preparation process is as in example 1.
Example 4
This example provides an oral care toothpaste (100g) of a formulation which differs from example 1 only in 0.275g cannabidiol and 0.275g sodium azulene sulfonate, the other components and levels being maintained.
The preparation process is as in example 1.
Example 5
This example provides an oral care toothpaste (100g) of the formulation which differs from example 1 only in 0.52g cannabidiol and 0.03g sodium azulene sulfonate, the other components and levels being maintained.
The preparation process is as in example 1.
Example 6
This example provides an oral care toothpaste (100g) of the formulation which differs from example 1 only in 0.54g cannabidiol, 0.01g sodium azulene sulfonate, and the other components and levels were kept constant.
The preparation process is as in example 1.
Example 7
This example provides an oral care toothpaste (100g) of the formulation which differs from example 1 only in 0.20g cannabidiol, 0.35g sodium azulene sulfonate, and the other components and levels were kept constant.
The preparation process is as in example 1.
Example 8
This example provides an oral care toothpaste (100g) of the formulation which differs from example 1 only in 0.5g cannabidiol, 0.005g sodium azulene sulfonate, and the other components and levels were kept constant.
The preparation process is as in example 1.
Example 9
This example provides an oral care toothpaste (100g) of the formulation which differs from example 1 only in 0.5g cannabidiol, 0.001g sodium azulene sulfonate, and the other components and levels were kept constant.
The preparation process is as in example 1.
Example 10
This example provides an oral care toothpaste (100g) of the formulation which differs from example 1 only in 0.15g cannabidiol, 0.40g sodium azulene sulfonate, and the other components and levels were kept constant.
The preparation process is as in example 1.
Comparative example 1
This comparative example provides an oral care toothpaste (100g) of a formulation which differs from example 1 only in that no cannabidiol is present and 0.55g of sodium azulene sulfonate, the other components and levels are maintained.
The preparation process is as in example 1.
Comparative example 2
This comparative example provides an oral care toothpaste (100g) of a formulation which differs from example 1 only in that sodium azulene sulfonate is absent and 0.55g cannabidiol, other components and levels are maintained.
The preparation process is as in example 1.
Evaluation test:
1. 240 volunteers suffering from moderate and severe oral ulcer and gum problems due to long-term eating of betel nuts are selected and randomly grouped into 12 groups of 20 persons, and the test flow is as follows: screening a research object; randomly grouping subjects according to inclusion and exclusion criteria, and simultaneously performing baseline examination; all subjects brushed their teeth 2 times a day, morning and evening, using a unified toothbrush, using the toothpastes prepared in examples 1-10 and comparative examples 1-2, using a daily brushing regimen; clinical examination; and (6) analyzing and evaluating data. The anti-inflammatory effect, the oral mucosa repair effect and the analgesic effect of the product are evaluated and tested together.
(1) Evaluation of anti-inflammatory Effect
The CPI probe was used at weeks 0, 4, 8, and 12, respectively, in combination with visual and exploratory visits. All teeth except the third permanent molars were examined and 6 facets were examined per tooth. The score for each tooth was the average of 6 facet scores and the individual score was the average of each tooth score. The scoring criteria were:
0: the gum is healthy;
0-1: mild inflammation of the gums: the color of the gum is slightly changed and slightly edematous, and bleeding is avoided during probing;
1-2: moderate inflammation of the gums: the gum is red, the edema is bright, and bleeding is detected;
2-3: severe inflammation of the gums: the gums are markedly inflamed or ulcerated and have a tendency to bleed spontaneously.
The results are shown in table 1:
TABLE 1
As can be seen from the data in Table 1: the oral care composition according to the present invention has excellent oral anti-inflammatory effect, and after 12 weeks using the product, serious inflammation of gums is converted into mild inflammation, and the data of comparative examples 1 to 10 and comparative examples 1 to 2 show that: the cannabidiol and the sodium azulene sulfonate have a synergistic effect in oral care, compared with single cannabidiol or sodium azulene sulfonate, the composition consisting of the cannabidiol and the sodium azulene sulfonate has a better anti-inflammatory effect, and when the mass ratio of the sodium azulene sulfonate to the cannabidiol meets 2:1-1:100, the effect is better, and when the mass ratio meets the range of 2:1-1:30, the effect is best.
(2) Evaluation of oral mucosa repair Effect
Evaluation was performed after 5 days of use, with the evaluation criteria:
and (3) curing: the ulcer is completely cured and the pain disappears
Improvement: reduced ulcer area or reduced ulcer
And (4) invalidation: the ulcer is not healed and pain exists
The results are shown in table 2:
TABLE 2
As can be seen from the data in Table 2: the oral care composition has good oral mucosa repairing effect, most of patients have repaired oral mucosa after using the product for 5 days, and the data of comparative examples 1-10 and comparative examples 1-2 show that: the cannabidiol and the sodium azulene sulfonate have a synergistic effect in oral care, and compared with the cannabidiol or the sodium azulene sulfonate alone, the composition consisting of the cannabidiol and the sodium azulene sulfonate has a better oral mucosa repair effect.
(3) Evaluation of analgesic Effect
Evaluation was performed after 5 days of use, with the evaluation criteria:
the method has the following advantages: the pain is obviously relieved;
in general: pain is reduced but not significantly;
and (4) invalidation: the pain was not reduced.
The results are shown in Table 3:
TABLE 3
As can be seen from the data in Table 3: the oral care composition according to the present invention has excellent analgesic effect, and the gingival pain symptoms are significantly improved after 5 days using the product, and the data of comparative examples 1 to 10 and comparative example 1 show that: the cannabidiol and the sodium azulene sulfonate have a synergistic effect in oral care, and compared with the single sodium azulene sulfonate, the composition consisting of the cannabidiol and the sodium azulene sulfonate has a better analgesic effect.
2. The test was carried out using guinea pigs suffering from gingivitis artificially, and 10 mice per group were used to produce artificial gingivitis by pricking the left gingiva of the guinea pig and the upper and lower two parts. After 24 hours from the occurrence of inflammation, the inflammation was observed by the degree of swelling, and based on this, 0.02g of the toothpastes prepared in examples 1 to 10 and comparative examples 1 to 2 were applied to the affected part, and gum conditions were observed and recorded on days 0, 2, 4, 6 and 8 of use, respectively. The scoring is fine as follows:
normal score of 0
Slight red and swollen with 0-1 point
1-2 points of marked red and swollen
Severe red swelling and slight ulcer 2-3 points
Severe red swelling and severe ulcer on a 3-4 point scale
The results are shown in Table 4:
TABLE 4
| Group of | Day 0 | Day 2 | Day 4 | Day 6 | Day 8 |
| Example 1 | 3.83 | 2.99 | 2.01 | 1.23 | 0.45 |
| Example 2 | 3.85 | 3.08 | 2.15 | 1.38 | 0.60 |
| Example 3 | 3.90 | 3.00 | 2.10 | 1.19 | 0.38 |
| Example 4 | 3.84 | 3.04 | 2.18 | 1.34 | 0.50 |
| Example 5 | 3.87 | 3.02 | 2.15 | 1.36 | 0.48 |
| Example 6 | 3.81 | 2.99 | 2.18 | 1.36 | 0.53 |
| Example 7 | 3.79 | 2.87 | 2.06 | 1.26 | 0.49 |
| Example 8 | 3.82 | 3.19 | 2.45 | 1.44 | 0.84 |
| Example 9 | 3.87 | 3.25 | 2.39 | 1.41 | 0.90 |
| Example 10 | 3.84 | 3.15 | 2.40 | 1.77 | 0.89 |
| Comparative example 1 | 3.79 | 3.15 | 2.45 | 1.89 | 1.15 |
| Comparative example 2 | 3.82 | 3.14 | 2.42 | 1.85 | 1.20 |
From the data in table 4, it can be seen that: the oral care composition according to the present invention has excellent oral anti-inflammatory effect, and the redness and ulceration of the gum of guinea pigs are significantly improved after 12 weeks using the product, and the data of comparative examples 1 to 10 and comparative examples 1 to 2 show that: the cannabidiol and the sodium azulene sulfonate have a synergistic effect in oral care, compared with single cannabidiol or sodium azulene sulfonate, the composition consisting of the cannabidiol and the sodium azulene sulfonate has a better anti-inflammatory effect, and when the mass ratio of the sodium azulene sulfonate to the cannabidiol meets 2:1-1:100, the effect is better, and when the mass ratio meets the range of 2:1-1:30, the effect is best.
The applicants state that the present invention is illustrated by the above examples of an oral care composition and its use, but the present invention is not limited to the above examples, i.e. it is not meant that the present invention must be practiced by relying on the above examples. It should be understood by those skilled in the art that any modification of the present invention, equivalent substitutions of the raw materials of the product of the present invention, addition of auxiliary components, selection of specific modes, etc., are within the scope and disclosure of the present invention.
The preferred embodiments of the present invention have been described in detail, however, the present invention is not limited to the specific details of the above embodiments, and various simple modifications may be made to the technical solution of the present invention within the technical idea of the present invention, and these simple modifications are within the protective scope of the present invention.
It should be noted that the various technical features described in the above embodiments can be combined in any suitable manner without contradiction, and the invention is not described in any way for the possible combinations in order to avoid unnecessary repetition.
Claims (10)
1. An oral care composition comprising cannabidiol and sodium azulene sulfonate.
2. The oral care composition of claim 1, wherein the mass ratio of sodium azulene sulfonate to cannabidiol in the oral care composition is from 2:1 to 1: 100.
3. The oral care composition of claim 1, wherein the mass ratio of sodium azulene sulfonate to cannabidiol in the oral care composition is from 2:1 to 1: 30.
4. Use of an oral care composition according to any one of claims 1 to 3 in the manufacture of an oral care product such as a toothpaste, a dentifrice, a mouthwash, a mouth spray, a mouth mask, a chewing gum or a buccal tablet.
5. An oral care toothpaste comprising the oral care composition of claim 1 and a toothpaste excipient.
6. The oral care toothpaste of claim 5, wherein said toothpaste excipient comprises a humectant, an abrasive, a binder, a surfactant, and a preservative;
preferably, the toothpaste auxiliary material also comprises a sweetening agent.
7. The oral care toothpaste of claim 6, wherein the humectant comprises any one or a combination of at least two of glycerin, sorbitol, propylene glycol, polyethylene glycol, or xylitol;
Preferably, the abrasive comprises any one or a combination of at least two of calcium carbonate, silica, aluminum hydroxide, calcium hydrogen phosphate dihydrate or calcium pyrophosphate;
preferably, the glue comprises any one or a combination of at least two of cellulose gum, xanthan gum or natural gum.
8. The oral care toothpaste of claim 6, wherein the surfactant comprises any one or a combination of at least two of sodium lauryl sulfate, sodium lauroyl sarcosinate, or sodium cocoyl glycinate;
preferably, the preservative comprises any one or a combination of at least two of methyl hydroxybenzoate and sodium salt thereof, ethyl hydroxybenzoate and sodium salt thereof, propyl hydroxybenzoate and sodium salt thereof, or sodium benzoate;
preferably, the sweetener comprises sodium saccharin and/or sucralose.
9. The oral care toothpaste according to any one of claims 5 to 8, wherein said oral care toothpaste comprises, in parts by weight: 0.1-2 parts of oral care composition, 20-75 parts of humectant, 10-50 parts of abrasive, 0.2-2 parts of adhesive, 1-2 parts of surfactant and 0.1-0.5 part of preservative.
10. The method of making an oral care toothpaste according to any one of claims 5 to 8 wherein the method of making comprises: mixing the components of the formula with water, stirring, homogenizing, grinding, degassing, cooling and aging.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911401585.7A CN111973480A (en) | 2019-12-30 | 2019-12-30 | Oral care composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911401585.7A CN111973480A (en) | 2019-12-30 | 2019-12-30 | Oral care composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111973480A true CN111973480A (en) | 2020-11-24 |
Family
ID=73442277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911401585.7A Pending CN111973480A (en) | 2019-12-30 | 2019-12-30 | Oral care composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111973480A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023009877A1 (en) * | 2021-07-30 | 2023-02-02 | Demetrix, Inc. | Use of cannabinoid compounds in oral care compositions to inhibit the growth of p. gingivalis |
| CN115990149A (en) * | 2021-10-18 | 2023-04-21 | 云南汉盟制药有限公司 | Antibacterial anti-inflammatory repair composition and preparation method and application thereof |
-
2019
- 2019-12-30 CN CN201911401585.7A patent/CN111973480A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023009877A1 (en) * | 2021-07-30 | 2023-02-02 | Demetrix, Inc. | Use of cannabinoid compounds in oral care compositions to inhibit the growth of p. gingivalis |
| CN115990149A (en) * | 2021-10-18 | 2023-04-21 | 云南汉盟制药有限公司 | Antibacterial anti-inflammatory repair composition and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6503483B2 (en) | Dental formulation | |
| EP1952801A1 (en) | Oral cavity care curative and prophylactic composition | |
| US20070110683A1 (en) | Oral care formulation | |
| CN106924106B (en) | A toothpaste for inhibiting plaque and reducing inflammation of the gums | |
| JP7463429B2 (en) | Oral Composition | |
| CN108245552B (en) | Composition for oral cavity and application thereof | |
| CN111973480A (en) | Oral care composition and application thereof | |
| US20070098650A1 (en) | Dental formulation | |
| CA2441940A1 (en) | Dental formulation | |
| KR102315355B1 (en) | Composition for prevention or treatment or oral disease | |
| RU2293551C1 (en) | Composition for mouth cavity disease prophylaxis | |
| KR20190094987A (en) | Composition for prevention or treatment of oral disease comprising Ginkgo biloba extract | |
| EP2889026A1 (en) | Compositions and methods for the prevention and treatment of oral diseases | |
| US8871183B2 (en) | Composition for promoting and maintaining oral health | |
| RU2505283C1 (en) | Toothpaste composition | |
| KR20180047704A (en) | Composition for prevention or treatment of oral disease comprising Scutellaria baicalensis extract | |
| US20090232749A1 (en) | Compositions for the acute and/or long term treatment of periodontal diseases | |
| CN109044898A (en) | A kind of hemostasis oral cavity nursing agent of brilliant white fresh breath type | |
| KR20190094986A (en) | Composition for prevention or treatment of oral disease comprising Epimedium Herb extract | |
| AU2019100471A4 (en) | Methods and compositions for reducing tooth, root and dentin sensitivity | |
| CN107982145A (en) | A kind of antiseptic toothpaste containing Baical Skullcap root P.E | |
| CN113456546A (en) | Oral care solution | |
| CN116966123A (en) | Mouthwash for strengthening and protecting teeth and preparation method thereof | |
| CN114601760A (en) | Oral composition | |
| WO2006110183A2 (en) | Dental formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201124 |